Company

Bank

Analyst

Coverage

Opinion

Wk chg

2/22 cls

Chelsea Therapeutics

Ladenburg Thalmann

Juan Sanchez

Upgrade

Buy (from neutral)

114%

$1.69

International Ltd. (NASDAQ:CHTP)

Needham

Alan Carr

Upgrade

Buy (from hold)

Sanchez also set a $3.50 target after Chelsea said it will resubmit an NDA for Northera droxidopa to treat symptomatic neurogenic orthostatic hypotension (NOH) in late 2Q13. The decision comes after FDA said data from the company's Phase III Study 306B trial may be sufficient as the basis of the resubmission. Last March, the agency issued a complete response letter requesting data from an additional trial to show durability of effect over a 2-3 month period. Northera is an orally available synthetic precursor of norepinephrine.